Unknown

Dataset Information

0

Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial.


ABSTRACT: INTRODUCTION:This phase III, double-blind, randomised, placebo-controlled trial (and extension phase) was designed to assess the efficacy and safety of velmanase alfa (VA) in alpha-mannosidosis (AM) patients. METHODS:Twenty-five patients were randomised to weekly 1 mg/kg VA or placebo for 52 weeks. At study conclusion, placebo patients switched to VA; 23 patients continued receiving VA in compassionate-use/follow-on studies and were evaluated in the extension phase [last observation (LO)]. Co-primary endpoints were changes in serum oligosaccharide (S-oligo) and in the 3-min stair-climb test (3MSCT). RESULTS:Mean relative change in S-oligo in the VA arm was -77.6% [95% confidence interval (CI) -81.6 to -72.8] at week 52 and?-62.9% (95% CI -85.8 to -40.0) at LO; mean relative change in the placebo arm was -24.1% (95% CI -40.3 to -3.6) at week 52 and?-55.7% (95% CI -76.4 to -34.9) at LO after switch to active treatment. Mean relative change in 3MSCT at week 52 was -1.1% (95% CI -9.0 to 7.6) and?-?% (95% CI -13.4 to 6.5) for VA and placebo, respectively. At LO, the mean relative change was 3.9% (95% CI -5.5 to 13.2) in the VA arm and 9.0% (95% CI -10.3 to 28.3) in placebo patients after switch to active treatment. Similar improvement pattern was observed in secondary parameters. A post hoc analysis investigated whether some factors at baseline could account for treatment outcome; none of those factors were predictive of the response to VA, besides age. CONCLUSIONS:These findings support the utility of VA for the treatment of AM, with more evident benefit over time and when treatment is started in the paediatric age.

SUBMITTER: Borgwardt L 

PROVIDER: S-EPMC6326984 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial.

Borgwardt Line L   Guffon Nathalie N   Amraoui Yasmina Y   Dali Christine I CI   De Meirleir Linda L   Gil-Campos Mercedes M   Heron Bénédicte B   Geraci Silvia S   Ardigò Diego D   Cattaneo Federica F   Fogh Jens J   Van den Hout J M Hannerieke JMH   Beck Michael M   Jones Simon A SA   Tylki-Szymanska Anna A   Haugsted Ulla U   Lund Allan M AM  

Journal of inherited metabolic disease 20180530 6


<h4>Introduction</h4>This phase III, double-blind, randomised, placebo-controlled trial (and extension phase) was designed to assess the efficacy and safety of velmanase alfa (VA) in alpha-mannosidosis (AM) patients.<h4>Methods</h4>Twenty-five patients were randomised to weekly 1 mg/kg VA or placebo for 52 weeks. At study conclusion, placebo patients switched to VA; 23 patients continued receiving VA in compassionate-use/follow-on studies and were evaluated in the extension phase [last observati  ...[more]

Similar Datasets

| S-EPMC4515982 | biostudies-literature
| S-EPMC4289734 | biostudies-literature
| S-EPMC6817985 | biostudies-literature
| S-EPMC10009502 | biostudies-literature
| S-EPMC2815998 | biostudies-literature
| S-EPMC4546310 | biostudies-literature
| S-EPMC7523268 | biostudies-literature
| S-EPMC7194454 | biostudies-literature
| S-EPMC3610091 | biostudies-literature
| S-EPMC8560642 | biostudies-literature